Surgepays Q1 2024 Adj EPS $0.07 Misses $0.20 Estimate, Sales $31.429M Beat $29.907M Estimate
Portfolio Pulse from Benzinga Newsdesk
Surgepays reported Q1 2024 adjusted EPS of $0.07, missing the $0.20 estimate, but its sales of $31.429M exceeded the $29.907M forecast. This represents a 9.62% decrease in sales compared to the same period last year.
May 13, 2024 | 8:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Surgepays' Q1 2024 earnings report showed a significant miss on EPS estimates but a slight beat on revenue forecasts, with a year-over-year decrease in sales.
The miss on the EPS estimate by 65% is significantly negative, but the beat on sales forecasts and the fact that sales are only slightly down YOY might mitigate the negative impact on the stock price. The mixed results present a complex picture for investors, potentially leading to short-term volatility as the market digests both the positive and negative aspects of the report.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100